What it is: A once-daily injectable GLP-1 hormone analog FDA approved for both type 2 diabetes (Victoza) and chronic weight management (Saxenda).
Research suggests: The LEADER cardiovascular outcomes trial established a 13% reduction in major cardiovascular events in diabetic patients; weight trials showed 5-8% average body weight loss.
Best for: Metabolic health and weight management researchers
Key thing to know: Once-daily injection and lower average weight loss than semaglutide have made it a second-line option in many settings, though it remains clinically relevant.
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, approved by the FDA for type 2 diabetes management (marketed as Victoza) and for chronic weight management (marketed as Saxenda). It was among the first GLP-1 receptor agonists to demonstrate cardiovascular outcomes benefits in a major clinical outcomes trial (LEADER), a milestone that shaped the entire GLP-1 drug class.
As a synthetic analog of native GLP-1, liraglutide has a fatty acid chain attached that extends its half-life to approximately 13 hours, allowing once-daily subcutaneous injection. This distinguishes it from older, shorter-acting GLP-1 compounds and was a design advance that preceded the longer-acting weekly formulations like semaglutide.
Researchers study liraglutide for type 2 diabetes glycemic control, chronic weight management in obesity, cardiovascular risk reduction, non-alcoholic fatty liver disease, and neuroprotective effects in models of neurodegeneration. Its long clinical track record makes it a reference compound against which newer metabolic peptides are frequently benchmarked.
How it works.
Liraglutide binds to and activates the GLP-1 receptor, which is expressed in the pancreas, brain, gastrointestinal tract, heart, and kidneys. In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion, meaning it increases insulin release only when blood glucose is elevated. This glucose-dependency is a key safety feature that limits hypoglycemia risk compared to older insulin secretagogues.
In the hypothalamus and brainstem, liraglutide activates satiety centers and reduces appetite signaling. It slows gastric emptying, which extends the feeling of fullness after eating and blunts post-meal glucose spikes. These combined effects on appetite, gastric motility, and insulin secretion produce the weight and glycemic improvements observed in clinical trials.
The cardiovascular benefits documented in the LEADER trial are thought to involve multiple pathways: reduced inflammation, improved endothelial function, modest reductions in blood pressure, and potentially direct cardiac GLP-1 receptor effects. The full mechanism underlying the cardiovascular outcomes benefit is still an active area of research.
What the research shows.
Liraglutide has one of the strongest evidence profiles of any compound in the metabolic peptide category. It holds FDA approval for two separate indications, has been evaluated in multiple large Phase 3 registration trials, and has a major cardiovascular outcomes trial (LEADER, n=9340) with published hard endpoint data showing reduced rates of major adverse cardiovascular events in high-risk patients with type 2 diabetes.
Weight loss efficacy has been demonstrated in the SCALE program trials, which established the evidence base for the Saxenda indication. Head-to-head trials against semaglutide (SUSTAIN 7) confirmed liraglutide's position as clinically effective while also documenting that once-weekly semaglutide produces greater weight and glycemic reductions at standard doses. This head-to-head data is itself a marker of the compound's mature evidence base.
Long-term safety data from over a decade of post-marketing surveillance strengthens the profile further. Liraglutide remains the most comprehensively studied daily-injection GLP-1 receptor agonist and serves as the clinical benchmark for the class.
Biomarkers to review first.
Research and clinical protocols for liraglutide consistently reference the following baseline biomarkers. These establish metabolic health context and allow clinicians to track meaningful changes during a protocol period.
What it's commonly researched with.
In the research context, liraglutide is primarily studied as a monotherapy. The compounds below appear alongside liraglutide in comparison studies, complementary metabolic research, or as next-generation successors that researchers frequently cross-reference. These represent what the literature has examined, not protocol recommendations.